Key result
Patients with ongoing acute kidney injury during admission for acute decompensated heart failure had a increased risk of death compared to those without acute kidney injury.
Why the study?
AKI in ADHF encompasses a broad spectrum of phenotypes with disparate outcomes, prompting evaluation of the impact of ongoing AKI on prognosis and cardiorenal outcomes.
Does ongoing acute kidney injury predict mortality and adverse cardiorenal outcomes in patients admitted with acute decompensated heart failure?
Cohort (n=271)
Yes
Does ongoing acute kidney injury predict mortality and adverse cardiorenal outcomes in patients admitted with acute decompensated heart failure?
Answers are grounded in this paper and cite their sources.
Ongoing acute kidney injury in acute decompensated heart failure is a potent prognostic indicator for significantly increased near-term mortality and cardiorenal complications.
BACKGROUND: Acute kidney injury (AKI) in the context of acute decompensated heart failure (ADHF) encompasses a broad spectrum of phenotypes with associated disparate outcomes. We evaluate the impact of 'ongoing AKI' on prognosis and cardiorenal outcomes and describe predictors of 'ongoing AKI'. METHODS: A prospective multicentre observational study of patients admitted with ADHF requiring intravenous furosemide was completed, with urinary angiotensinogen (uAGT) measured at baseline. AKI was defined using Kidney Disease Improving Global Outcomes (KDIGO) AKI criteria. AKI recovery status was defined as 'no AKI', 'recovered AKI' or 'ongoing AKI' based on renal function at hospital discharge. Event-free survival analysis was performed to predict death and cardiorenal outcomes at hospital discharge and 6-month follow-up. Multinomial logistic regression was performed to identify predictors of ongoing AKI. Multiclass receiver operator curve analysis was performed to evaluate the relationship between renin-angiotensin system (RAS) blockers and uAGT in predicting ongoing AKI. RESULTS: Among 271 enrolled patients, 121 (44.6%) patients developed AKI, of whom 62 patients had ongoing AKI. Ongoing AKI was associated with increased risk of death (HR 6.89, p<0.001), in-hospital end-stage kidney disease (HR 44.39, p<0.001), 6-month composite of death, transplant, left ventricular assist device and heart failure hospitalisation (HR 3.09, p<0.001), and 6-month composite major adverse kidney events (HR 5.71, p<0.001). Elevated baseline uAGT levels, chronic beta-blocker and thiazide diuretic therapy, and lack of RAS blocker prescription at recruitment were associated with ongoing AKI. While uAGT levels were lower with RAS blocker prescription, in patients with ongoing AKI, uAGT levels were elevated regardless of RAS blocker status. CONCLUSION: Patients experiencing ongoing AKI during ADHF admission were at increased risk of death and other adverse cardiorenal outcomes. Differential uAGT response in patients receiving RAS blockers with ongoing AKI suggests biomarkers may be helpful in predicting treatment responses and cardiorenal outcomes.
No takes yet. Share an insight, caveat, or question.
Barua et al. (2025) conducted a cohort in Acute decompensated heart failure (n=271). Ongoing acute kidney injury vs. No acute kidney injury was evaluated on All-cause mortality (HR 6.89, 95% CI 3.01-15.75, p=<0.001). Patients with ongoing acute kidney injury during admission for acute decompensated heart failure had a increased risk of death compared to those without acute kidney injury.
Synapse has enriched 10 related papers. Consider them for comparative context: